Base Pair Biotechnologies, Inc.

Base Pair Biotechnologies, Inc. focuses on the discovery and development of aptamers, providing innovative solutions tailored for drug discovery, diagnostics, and therapeutic applications. Founded in 2011 and headquartered in Pearland, US, Base Pair Biotechnologies specializes in aptamer technology. The company has made one notable deal in its history, securing a Series A funding round of USD 3.

2 mn in November 2017, led by new investors Base Pair Canada and Eventi Capital Partners, with Biotex also participating. Bill Jackson, who has previously founded other ventures, serves as the CEO and founder of the company. Base Pair Biotechnologies specializes in the discovery and development of aptamers, which are short, single-stranded nucleic acids capable of binding specifically to target molecules, such as proteins and small molecules. Their offerings include custom aptamer discovery and development, bioinformatics for aptamer selection, affinity determination, assay development services, and unique tools like the AptaTracker™ for monitoring aptamer interactions.

These solutions are designed to address scientific challenges in drug discovery, diagnostics, and therapeutic applications, catering to pharmaceutical companies, biotechnology firms, and research institutions globally. Revenue for Base Pair Biotechnologies is generated through direct B2B transactions, primarily via contracts for custom aptamer development. Clients engage with the company through consultative projects, which include milestone payments tied to project phases. Their proprietary Multiplex SELEX™ technology serves as a cornerstone of their revenue stream, utilized for various applications.

While specific pricing information is not disclosed, services are provided at competitive rates, considering the bespoke nature of the aptamer discovery process. Base Pair Biotechnologies plans to leverage the USD 3. 2 mn raised in their Series A funding to further develop their product line and expand into new markets. The funding will support the launch of advanced aptamer products designed for emerging diagnostic applications, with targeted releases planned for 2024.

Additionally, the company aims to enter European and Asian markets by 2025, broadening their client base and enhancing their service capabilities.